MX2012006622A - Composiciones acuosas estables de profarmacos de agonista de prostaglandina y metodos para el uso de estas. - Google Patents

Composiciones acuosas estables de profarmacos de agonista de prostaglandina y metodos para el uso de estas.

Info

Publication number
MX2012006622A
MX2012006622A MX2012006622A MX2012006622A MX2012006622A MX 2012006622 A MX2012006622 A MX 2012006622A MX 2012006622 A MX2012006622 A MX 2012006622A MX 2012006622 A MX2012006622 A MX 2012006622A MX 2012006622 A MX2012006622 A MX 2012006622A
Authority
MX
Mexico
Prior art keywords
compositions
methods
prostglandin
aqueous compositions
stable aqueous
Prior art date
Application number
MX2012006622A
Other languages
English (en)
Spanish (es)
Inventor
Robert M Burk
Wha Bin Im
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43503864&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2012006622(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of MX2012006622A publication Critical patent/MX2012006622A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/559—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing hetero atoms other than oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2012006622A 2009-12-09 2010-11-05 Composiciones acuosas estables de profarmacos de agonista de prostaglandina y metodos para el uso de estas. MX2012006622A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26789709P 2009-12-09 2009-12-09
PCT/US2010/055590 WO2011071620A1 (en) 2009-12-09 2010-11-05 Stable aqueous compositions of prostglandin agonist prodrugs and methods for use thereof

Publications (1)

Publication Number Publication Date
MX2012006622A true MX2012006622A (es) 2012-08-15

Family

ID=43503864

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012006622A MX2012006622A (es) 2009-12-09 2010-11-05 Composiciones acuosas estables de profarmacos de agonista de prostaglandina y metodos para el uso de estas.

Country Status (16)

Country Link
US (2) US20110136872A1 (https=)
EP (1) EP2509582A1 (https=)
JP (2) JP5955774B2 (https=)
KR (1) KR20120106788A (https=)
CN (1) CN102762195B (https=)
AR (1) AR078929A1 (https=)
AU (1) AU2010328555B2 (https=)
CA (1) CA2783707A1 (https=)
CL (1) CL2012001545A1 (https=)
IL (1) IL220240A0 (https=)
MX (1) MX2012006622A (https=)
NZ (1) NZ600577A (https=)
RU (1) RU2012127869A (https=)
SG (1) SG181600A1 (https=)
TW (1) TW201138766A (https=)
WO (1) WO2011071620A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2711425T3 (es) 2012-08-27 2019-05-03 Allergan Inc Espesamiento de la córnea central reducido mediante el uso de profármacos de éster hidrófilos de beta-clorociclopentanos
KR101535825B1 (ko) 2012-09-25 2015-07-10 엘지디스플레이 주식회사 표시장치 및 이의 라인결함 검출방법
JP6626831B2 (ja) * 2014-02-20 2019-12-25 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ ベータ−クロロシクロペンタンの親水性エステルプロドラッグの使用による角膜中心肥厚の減少
ES2757798T3 (es) 2014-10-02 2020-04-30 Allergan Inc Profármacos de éster de gamma-lactamas y su uso

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2021316C (en) * 1989-07-27 2000-10-24 Ming Fai Chan Intraocular pressure reducing 11-acyl prostaglandins
US5034413A (en) 1989-07-27 1991-07-23 Allergan, Inc. Intraocular pressure reducing 9,11-diacyl prostaglandins
US5028624A (en) * 1989-07-27 1991-07-02 Allergan, Inc. Intraocular pressure reducing 9,15-diacyl prostaglandins
US4994274A (en) * 1989-07-27 1991-02-19 Allergan, Inc. Intraocular pressure reducing 11,15-diacyl prostaglandins and method of using
JP2002521332A (ja) * 1998-07-21 2002-07-16 メルク エンド カムパニー インコーポレーテッド 高眼圧治療用眼薬組成物
DK1321144T3 (da) * 2000-09-13 2011-03-07 Santen Pharmaceutical Co Ltd Øjendråber
EP1532981B1 (en) * 2002-08-23 2007-09-26 Santen Pharmaceutical Co., Ltd. Stable eye drops containing latanoprost as the active ingredient
SI1759702T1 (sl) * 2004-05-26 2009-06-30 Bayardo Arturo Jimenez Postopek pripravljanja oftalmiäśne raztopine latanoprosta in tako proizvedena raztopina
US20050276867A1 (en) * 2004-06-09 2005-12-15 Allergan, Inc. Stabilized compositions comprising a therapeutically active agent and an oxidizing preservative
EP1856042B1 (en) * 2005-03-10 2012-06-27 Allergan, Inc. Substituted gamma lactams as therapeutic agents
WO2008096804A1 (ja) * 2007-02-07 2008-08-14 Teika Pharmaceutical Co., Ltd. ラタノプロスト含有点眼剤
UA103616C2 (ru) * 2008-04-24 2013-11-11 Аллерган, Инк. Замещенные гамма-лактамы как терапевтические агенты
EP2127638A1 (en) * 2008-05-30 2009-12-02 Santen Pharmaceutical Co., Ltd Method and composition for treating ocular hypertension and glaucoma

Also Published As

Publication number Publication date
TW201138766A (en) 2011-11-16
SG181600A1 (en) 2012-07-30
US20160220677A1 (en) 2016-08-04
EP2509582A1 (en) 2012-10-17
CN102762195B (zh) 2016-05-18
IL220240A0 (en) 2012-07-31
JP2013513606A (ja) 2013-04-22
JP2016056207A (ja) 2016-04-21
RU2012127869A (ru) 2014-01-20
WO2011071620A1 (en) 2011-06-16
CN102762195A (zh) 2012-10-31
AU2010328555A1 (en) 2012-07-05
JP5955774B2 (ja) 2016-07-20
CL2012001545A1 (es) 2012-08-31
NZ600577A (en) 2014-10-31
AU2010328555B2 (en) 2016-05-26
CA2783707A1 (en) 2011-06-16
US20110136872A1 (en) 2011-06-09
AR078929A1 (es) 2011-12-14
KR20120106788A (ko) 2012-09-26

Similar Documents

Publication Publication Date Title
PH12016500216B1 (en) Stable pharmaceutical composition and methods of using same
PH12012500903A1 (en) N1 - pyrazolospiroketone acetyl-coa carboxylase inhibitors
WO2010018113A3 (en) Bi-aryl aminotetralines
TW200801000A (en) Spiroindolinone derivatives
MY162499A (en) Methylphenidate-prodrugs, processes of making and using the same
SG10201803862UA (en) Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof
CA2818187C (en) Bromodomain inhibitors and uses thereof
WO2010018109A3 (en) Substituted aminotetralines
GEP20166474B (en) Pyrazolospiroketone derivatives for use as acetyl-coa carboxylase inhibitors
TW200612958A (en) Substituted imidazole derivatives
PH12014501937B1 (en) Pharmaceutical composition containing an antivirally active dihydroquinazoline derivative
HK1202415A1 (en) Pharmaceutical compositions comprising dgla, 15-ohepa, and/or 15-hetre and methods of use thereof
TN2009000287A1 (en) Cyclized derivatives as eg-5inhibitors
UA116894C2 (uk) Похідні піразину як агоністи канабіноїдного рецептора 2
SI1753723T1 (sl) Substituirani kinolinski derivati kot mitotiäśni kinesinski inhibitorji
WO2012138713A3 (en) Multifunctional radical quenchers for the treatment of mitochondrial dysfunction
EP2328550A4 (en) MUKOADHÄRENTE COMPOSITIONS AND ITS USE
MX2012006622A (es) Composiciones acuosas estables de profarmacos de agonista de prostaglandina y metodos para el uso de estas.
WO2011151436A3 (en) Azepin-derivatives as derivatives as g- protein coupled receptor (gpr43) agonists
TW200800951A (en) Substituted imidazole compounds as KSP inhibitors
EA201490363A1 (ru) Новые составы на основе (триметоксифениламино)пиримидинилов
MX2009008548A (es) Formulaciones de olopatadina para administracion nasal topica.
WO2010095877A3 (en) Aqueous nanoemulsion composition containing conjugated linoleic acid
WO2008042928A3 (en) Oxadiazole and thiadiazole derivatives as mitotic kinesin inhibitors and methods of use thereof
MX2012005447A (es) Combinacion farmacéutica de compuesto de prostaglandina y nsaid (medicamentos antiinflamantorios no esteroideos) para el tratamiento de glaucoma e hipertensión ocular.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal